REQUEST A DEMO
Total
USD $0.00
Search more companies

Clinomics Inc. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Clinomics Inc. Profile Updated: December 12, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Clinomics Inc. is based in South Korea, with the head office in Ulsan. The enterprise operates in the Pharmaceutical and Medicine Manufacturing industry. Clinomics Inc. was incorporated on June 21, 2011. The total number of employees is currently 64 (2024). From the latest financial highlights, Clinomics Inc. reported a net sales revenue drop of 95.74% in Q12026. Its’ total assets recorded a negative growth of 40.66%. The net profit margin of Clinomics Inc. increased by 1420.38% in 2026.

Headquarters
Suite 301-3, Bldg. 110, Unist, 50, Unist-Gil, Eonyang-Eup, Ulju-Gun
Ulsan; Ulsan;

Contact Details: Purchase the Clinomics Inc. report to view the information.

Website: http://www.clinomics.com

Basic Information
Total Employees:
Purchase the Clinomics Inc. report to view the information.
Outstanding Shares:
Purchase the Clinomics Inc. report to view the information.
Registered Capital:
Purchase the Clinomics Inc. report to view the information.
Financial Auditors:
Purchase the Clinomics Inc. report to view the information.
Incorporation Date:
June 21, 2011
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜클리노믹스
Company Performance
Financial values in the chart are available after Clinomics Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-95.74%▼
Total Operating Revenue
-70.52%▼
Operating Profit
98.15%▲
EBITDA
99.33%▲
Net Profit/Loss for the Period
99.12%▲
Total Assets
-40.66%▼
Total Equity
58.32%▲
Operating Profit Margin
686.94%▲
Net Profit Margin
1420.38%▲
Return on Equity (ROE)
-62.02%▼
Debt / Equity
149.47%▲
Quick Ratio
-0.11%▼
Cash Ratio
-0.17%▼

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?